PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 23, 2026Journal of Translational Medicine0 citationsOpen Access

Serine Hydroxymethyltransferase (SHMT) in biology and disease: molecular mechanisms and therapeutic targeting

JLJia-Ying LiSoochow UniversityXZXueqing ZhangChina Three Gorges UniversityRSRui ShengFuyang Normal University

Key Points

  • The aim is to review the molecular mechanisms of SHMT1/2 and their roles in various diseases, particularly cancers and liver diseases.
  • Concise review of SHMT1/2 functions and their regulatory roles in metabolic pathways.
  • Analysis of disease associations with SHMT-mediated one-carbon metabolism.
  • Discussion on therapeutic targeting of SHMT inhibitors in clinical applications.
  • Dysregulated SHMT activity is linked to multiple cancers and liver diseases.
  • SHMT1/2 perform both enzymatic and non-enzymatic roles affecting disease progression.
  • SHMT inhibitors show promise in targeted cancer therapies.

Abstract

Serine Hydroxymethyltransferase 1 and 2 (SHMT1/2), as key enzymes in folate metabolism, regulate diverse physiological processes through one-carbon metabolism, including nucleotide biosynthesis, methylation reactions, and redox homeostasis. As a form of metabolic reprogramming, dysregulated SHMT-mediated one-carbon metabolism has been increasingly reported in various human cancers and liver metabolic diseases. Therefore, a concise review of its regulatory roles and disease-associated functions is necessary to clarify its biological and translational significance. This review summarizes the molecular functions of SHMT1/2, with particular emphasis on their central roles in the folate-methionine cycle and serine-glycine metabolic pathway. Beyond their canonical enzymatic activities, SHMT1/2 also exhibit critical non-enzymatic functions. Their activity is tightly regulated by transcription factors and post-translational modifications. SHMT1/2 play significant roles in multiple pathological conditions and are implicated in the initiation and progression of various cancers, such as ovarian, lung, liver, gastric, colorectal, and renal carcinomas. Moreover, SHMT-mediated one-carbon metabolism critically influences liver diseases (e.g., non-alcoholic fatty liver disease, steatohepatitis), inflammatory disorders (e.g., skin inflammation, osteoarthritis), and neurological diseases (e.g., schizophrenia, hypomyelinating leukodystrophy, stroke). Finally, this review discusses the clinical translational potential of SHMT inhibitors in cancer-targeted therapies, offering a theoretical basis for expanding the therapeutic applications of SHMT1/2 in diseases associated with dysregulated one-carbon metabolism. SHMT1/2 regulate diseases associated with dysregulated one-carbon metabolism through both their enzymatic and non-enzymatic functions. Particularly in cancer, they function as either oncogenes or tumor suppressors in a context-dependent manner, holding significant potential as diagnostic, prognostic, and therapeutic targets.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/69e9b6aa85696592c86eb089https://doi.org/10.1186/s12967-026-08044-x
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1RNA-mediated inhibition of mitochondrial SHMT2 impairs cancer cell proliferation2025 · 5 citations
  2. 2Metabolomics in Prediabetes and Diabetes: A Systematic Review and Meta-analysis2016 · 939 citations
  3. 3Roles of Mitochondrial Serine Hydroxymethyltransferase 2 (SHMT2) in Human Carcinogenesis2021 · 63 citations
  4. 4Discovery of W478, a novel SHMT2 inhibitor for the treatment of esophageal carcinoma2025 · 6 citations
  5. 5Metformin Is a Pyridoxal-5′-phosphate (PLP)-Competitive Inhibitor of SHMT22021 · 34 citations